Invariant natural killer T-cell therapy (Ambicion)

N/A

Report date: 2022/09/06 18:12:14

Base Information

Drug NameInvariant natural killer T-cell therapy (Ambicion)

Drug Alias NameiNKT cancer treatment - Ambicion

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy

Mechanisms of ActionT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesInstitute Physical Chemical Research (Riken)Ambicion

China Registration ClassN/A

Develop Information

Active CompaniesInstitute Physical Chemical Research (Riken)Ambicion

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A